Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From SITC and IBCG

鈥� An ASCO Reading Room selection

March 28, 2024

Ashish M. Kamat, MD, MBBS, Andrea B. Apolo, MD, Marek Babjuk, MD, PhD, Trinity J. Bivalacqua, MD, PhD, Peter C. Black, MD, FACS, FRCSC, Roger Buckley, MD, FRCSC, Matthew T. Campbell, MD, MS, Eva Comp茅rat, MD, PhD, Jason A. Efstathiou, MD, DPHIL, Petros Grivas, MD, PhD, Shilpa Gupta, MD, Neil J. Kurtz, MD, Donald Lamm, MD, FACS, Seth P. Lerner, MD, FACS, Roger Li, MD, David J. McConkey, PhD, Joan Palou Redorta, MD, PhD, Thomas Powles, MBBS, MD, MRCP, Sarah P. Psutka, MD, Neal Shore, MD, FACS, Gary D. Steinberg, MD, Richard Sylvester, ScD, J. Alfred Witjes, MD, PhD, and Matthew D. Galsky, MD

Journal of Clinical Oncology

This Reading Room is a collaboration between 麻豆传媒庐 and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Purpose

There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel.

Methods

Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually).

Results

The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text.

Conclusion

These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

Read an interview about the recommendations here and expert commentary about them here.

Read the full article

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From SITC and IBCG

Primary Source

Journal of Clinical Oncology

Source Reference:

麻豆传媒